

## INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY

ICGEB Campus, Aruna Asaf Ali Marg New Delhi - 110 067, India http://www.icgeb.org

Tel.: 91-11-26741358/61 91-11-26742357/60

91-11-26741007 Fax: 91-11-26742316

UIN No.: 0717UNO00161UNZ E-mail : icgeb@icgeb.res.in

Citation (summary) on the outstanding research work on which award is claimed in about 250 words signed by the nominator.

Novel prime-boost immunization strategies are required to control the global Tuberculosis (TB) pandemic, which claims approximately 3 lives every minute. Towards this, Dr Dwivedi has recently generated an immunogenic complex against M.tb which consists of promiscuous T-cell epitopes and TLR-ligands assembled in liposomes (PTLs; peptide-TLR agonist-liposomes). Intranasal delivery of PTL significantly reduced the bacterial burden in the infected mice by inducing robust M.tb specific polyfunctional immune-responses and long-lasting central memory responses thereby reducing the risk of TB recurrence (JCI Insight-2021). This molecule has been patented and is presently in National Phases of various South East Asian and African Countries. Interestingly, this complex (PTLs; peptide-TLR agonist-liposomes) induced significant activation of CD4<sup>+</sup>T cells and IFNy production in the PBMCs derived from PPD+ healthy individuals as compared to PPD- controls. Furthermore, intranasal delivery of PTLs significantly reduced the bacterial burden in the infected mice by inducing M.tb specific polyfunctional (IFN $\gamma$ <sup>+</sup>IL17<sup>+</sup>TNF $\alpha$ <sup>+</sup>IL2<sup>+</sup>) immune responses and longlasting central memory responses thereby reducing the risk of TB recurrence in DOTS treated infected animals. The transcriptome analysis of peptide-stimulated immune cells unveiled the molecular basis of enhanced protection. Furthermore, PTLs immunization significantly boosted the BCG-primed immune responses against TB. The greatly enhanced efficacy of BCG-PTLs vaccine model in controlling pulmonary TB projects PTLs as an adjunct vaccine against TB.

Place: New Delhi

Date: 28/08/2023

Signature of the Head of the Institution



Rambe VSoute.